CARsgen Therapeutics Co., Ltd.

13 clinical trials · Sponsor

Record	Firm	Date
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy (NCT06825845)	CARsgen Therapeutics Co., Ltd.	2025-03-31
A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma (NCT06659770)	CARsgen Therapeutics Co., Ltd.	2024-10-01
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection (NCT06560827)	CARsgen Therapeutics Co., Ltd.	2023-10-08
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer (NCT05911217)	CARsgen Therapeutics Co., Ltd.	2023-07-11
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (NCT04581473)	CARsgen Therapeutics Co., Ltd.	2020-10-23
Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers (NCT04404595)	CARsgen Therapeutics Co., Ltd.	2020-10-23
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (NCT04400383)	CARsgen Therapeutics Co., Ltd.	2020-06-04
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) (NCT03915184)	CARsgen Therapeutics Co., Ltd.	2019-09-25
Chimeric Antigen Receptor T Cells Targeting Glypican-3 (NCT03884751)	CARsgen Therapeutics Co., Ltd.	2019-08-15
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (NCT03994913)	CARsgen Therapeutics Co., Ltd.	2019-08-14
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) (NCT03975907)	CARsgen Therapeutics Co., Ltd.	2019-06-10

Track CARsgen Therapeutics Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.